1
|
Holekamp NM, Yaqub M, Ranade SV, Cantrell RA, Singh S, Gazzard G. Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants. Ophthalmol Ther 2024; 13:2303-2329. [PMID: 39090513 PMCID: PMC11341515 DOI: 10.1007/s40123-024-01001-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Accepted: 07/15/2024] [Indexed: 08/04/2024] Open
Abstract
OBJECTIVES To determine whether the types and rates of post-surgical complications associated with the Port Delivery System with ranibizumab (PDS) are comparable with those reported for other ocular implants that cross the sclera. METHODS Systematic literature reviews were conducted to determine the long-term (≥ 18-month) safety of ocular implants that cross the sclera in clinical trials and real-world studies. Complication types and rates were compared with those reported for the PDS in phase III clinical trials (Archway, Pagoda, and Pavilion). RESULTS Sixteen clinical trials (24 publications) and 43 real-world studies were identified reporting 30 complications in eyes with 15 implant types and 8 ocular diseases. Implants were associated with an acceptable, well-characterized safety profile, with most complications resolving spontaneously or with treatment. Device-related complications were reported in 0.7% (0.0-5.0%) of study eyes in clinical trials and 1.3% (0.0-14.5%) of eyes in real-world studies. Rates of conjunctival complications were 2.1% (0.0-22.8%) and 2.2% (0.9-4.6%), respectively. The overall types and rates of adverse events of special interest reported for the PDS in phase III trials (cataract, conjunctival bleb, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, endophthalmitis, implant dislocation, retinal detachment, and hyphema) were within the ranges reported for other ocular implants. CONCLUSIONS The rates of complications reported in phase III clinical trials for the PDS were within the ranges reported for other ocular implants that cross the sclera. This suggests that the long-term safety of the PDS is consistent with other ocular devices established in ophthalmology clinical practice. TRIAL REGISTRATION PROSPERO international prospective register of systematic reviews: CRD5202234129, CRD42022343129.
Collapse
Affiliation(s)
- Nancy M Holekamp
- Pepose Vision Institute, Chesterfield, MO, USA.
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
| | - Manejeh Yaqub
- Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, USA
| | - Shrirang V Ranade
- Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, USA
| | - Ronald A Cantrell
- Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, USA
| | | | - Gus Gazzard
- Institute of Ophthalmology, University College London, London, UK
- NIHR Moorsfield Biomedical Research Centre, Moorfield Eye Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
2
|
Halkiadakis I, Konstantopoulou K, Tzimis V, Papadopoulos N, Chatzistefanou K, Markomichelakis NN. Update on Diagnosis and Treatment of Uveitic Glaucoma. J Clin Med 2024; 13:1185. [PMID: 38592059 PMCID: PMC10931771 DOI: 10.3390/jcm13051185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/10/2024] [Accepted: 02/13/2024] [Indexed: 04/10/2024] Open
Abstract
Glaucoma is a common and potentially blinding complication of uveitis. Many mechanisms are involved alone or in combination in the pathogenesis of uveitic glaucoma (UG). In terms of diagnostic evaluation, the effects of inflammatory activity in the retinal nerve fiber layer may be a source of bias in the interpretation of optical coherence tomography measurements. For the successful treatment of UG, the control of intraocular inflammation specific to the cause or anti-inflammatory treatment, combined with IOP management, is mandatory. The early institution of specific treatment improves the prognosis of UG associated with CMV. The young age of UG patients along with increased failure rates of glaucoma surgery in this group of patients warrants a stepwise approach. Conservative and conjunctival sparing surgical approaches should be adopted. Minimally invasive surgical approaches were proved to be effective and are increasingly being used in the management of UG along with the traditionally used techniques of trabeculectomy or tubes. This review aims to summarize the progress that recently occurred in the diagnosis and treatment of UG.
Collapse
Affiliation(s)
- Ioannis Halkiadakis
- Ophthalmiatrion Athinon, Athens Eye Hospital, 10672 Athens, Greece; (K.K.); (V.T.); (N.P.)
| | | | - Vasilios Tzimis
- Ophthalmiatrion Athinon, Athens Eye Hospital, 10672 Athens, Greece; (K.K.); (V.T.); (N.P.)
| | - Nikolaos Papadopoulos
- Ophthalmiatrion Athinon, Athens Eye Hospital, 10672 Athens, Greece; (K.K.); (V.T.); (N.P.)
| | - Klio Chatzistefanou
- First Department of Ophthalmology, National and Kapodistrian University of Athens School of Medicine, Athens General Hospital “G. Gennimatas”, 11527 Athenbs, Greece;
| | | |
Collapse
|
3
|
Effect of guided Ahmed glaucoma valve implantation on corneal endothelial cells: A 2-year comparative study. PLoS One 2023; 18:e0278340. [PMID: 36787298 PMCID: PMC9928107 DOI: 10.1371/journal.pone.0278340] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 11/14/2022] [Indexed: 02/15/2023] Open
Abstract
PURPOSE To compare the effects of guided and non-guided Ahmed glaucoma valve (AGV) implantation on the corneal endothelium. METHODS Medical records of patients who underwent AGV implantation in the anterior chamber (AC) were reviewed retrospectively. The eyes were divided into two groups depending on the use of a guidance technique with spatula and a 4-0 nylon intraluminal stent. Specular microscopy was performed to measure corneal endothelial cell density (ECD) loss after surgery, and the rate of ECD change was calculated. Tube parameters were measured using anterior segment optical coherence tomography (AS-OCT). RESULTS The ECD loss during 2 years of follow-up was significantly lower in the guided AGV implantation (gAGV) group than in the non-guided implantation (ngAGV) group, and the rate of ECD change was -0.62 ± 1.23 and -1.42 ± 1.57%/month in the gAGV and ngAGV groups, respectively (p = 0.003). The mean tube-cornea distance (TCD) and mean tube-cornea angle (TCA) were significantly greater in the gAGV group than in the ngAGV group. The frequency of tube repositioning within 2 years after surgery was 0% in the gAGV group and 12.66% in the ngAGV group (p = 0.005). CONCLUSIONS The use of a guidance technique can reduce corneal endothelial loss during the first 2 years after AGV implantation in the AC. The tube was positioned at a more distant and wider angle from the cornea in the eyes of the gAGV group, which may have contributed to the reduced need for tube repositioning to prevent corneal decompensation.
Collapse
|
4
|
Beatson B, Wang J, Boland MV, Ramulu P, Schein O, Fliotsos MJ, Sulewski ME, Srikumaran D. Corneal Edema and Keratoplasty: Risk Factors in Eyes With Previous Glaucoma Drainage Devices. Am J Ophthalmol 2022; 238:27-35. [PMID: 34995525 DOI: 10.1016/j.ajo.2021.12.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 12/20/2021] [Accepted: 12/27/2021] [Indexed: 12/20/2022]
Abstract
PURPOSE To assess risk factors contributing to corneal decompensation following glaucoma drainage device (GDD) implantation. DESIGN Retrospective case control study. METHODS Records of 1610 eyes that underwent GDD implantation between June 1, 2009, and April 1, 2020, at the Johns Hopkins Wilmer Eye Institute were reviewed. Seventy-nine eyes (5%) developed corneal decompensation, of which 46 underwent keratoplasty. These 79 cases were matched with 220 controls. Cox proportional hazard models with robust standard error estimates to account for clustering at the matched-pair level were used to assess risk factors for corneal decompensation. Kaplan-Meier survival analysis analyzed time to corneal decompensation. RESULTS The mean (SD) age of cases and controls was 68 (12.3) and 60.5 (15.9) years, respectively. The mean time from GDD implantation to corneal decompensation was 32 months, and the cumulative probability of developing decompensation at 3, 6, and 9 years was 4.7%, 9.2%, and 14.8%, respectively. Final visual outcomes in cases were worse, with a final mean ± SD visual acuity (logMAR) of 1.96±1.25 relative to a mean±SD visual acuity of 1.11±1.36 in controls (P < .001). In the multivariable model, significant risk factors for corneal decompensation were increased age (adjusted hazard ratio [AHR] 1.39, 95% CI 1.18, 1.63; P ≤ .001), history of Fuchs dystrophy or iridocorneal endothelial syndrome (AHR 9.18, 95% CI 5.35, 15.74; P ≤ .001), and postoperative complications such as hypotony (AHR 3.25, 95% CI 1.85, 5.72; P ≤ .001) and tube-cornea touch (AHR 6.37, 95% CI 3.77, 10.75; P ≤ .001). CONCLUSIONS The risk of postoperative corneal decompensation is persistent over time. Patients receiving GDDs, particularly those with advanced age, preexisting corneal pathology, and postoperative complications, should be counseled regarding their increased risk for corneal decompensation.
Collapse
Affiliation(s)
- Bradley Beatson
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland
| | - Jiangxia Wang
- Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health (J.W.), Baltimore, Maryland
| | - Michael V Boland
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland; Massachusetts Eye and Ear, Harvard Medical School (M.V.B.), Boston, Massachusetts
| | - Pradeep Ramulu
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland
| | - Oliver Schein
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland
| | - Michael J Fliotsos
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland
| | - Michael E Sulewski
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland
| | - Divya Srikumaran
- From the Wilmer Eye Institute, Johns Hopkins University School of Medicine (B.B., M.V.B., P.R., O.S., M.J.F., M.E.S., D.S.), Baltimore, Maryland.
| |
Collapse
|